Key Insights• According to the research report, "United Arab Emirates EPA & DHA Market Outlook, 2031," published by Actual Market Research, the United Arab Emirates EPA & DHA Market is anticipated to add to more than USD 11.83 Million by 2026-31. The United Arab Emirates EPA & DHA market is expanding rapidly as the country faces a high and early-onset burden of cardiometabolic disease, a fast-growing and largely expatriate population, and rising consumer spending on preventive health and wellness. According to the Federal Competitiveness and Statistics Centre (FCSC), the UAE's population reached 11,294,243 in 2024, growing 5.6% year-over-year, driven by sustained inflows of working-age residents. Cardiovascular disease is the leading cause of death in the UAE, and clinicians have long noted that residents tend to develop cardiovascular disease around a decade or more earlier than the global average, reflecting high rates of obesity, diabetes, hypertension, smoking, and sedentary lifestyles. Low consumption of oily fish among many population groups and widespread vitamin and nutrient deficiencies are increasing physician and pharmacist recommendation of omega-3 supplementation. The growing clinical burden is placing additional pressure on the UAE's federal and emirate-level health authorities and consumer health sector to strengthen access to EPA and DHA through supplements, prescription medicines, infant nutrition, and fortified foods.• The UAE's EPA & DHA market is characterized by a highly import-dependent and premium-oriented ecosystem comprising international supplement brands, regional distributors, pharmacy chains, hypermarkets, e-commerce platforms, and specialized health stores. Pharmacy chains such as Aster, Life Pharmacy, BinSina, and Boots, alongside hypermarkets such as Carrefour and Lulu, and online platforms such as Noon, Amazon.ae, and iHerb, function as the primary distribution channels for omega-3 products.

International brands from the U.S., Europe, Australia, and Canada dominate the category, with consumers favoring high-strength fish oil, krill oil, and algal omega-3 in halal-certified formats. The UAE also serves as a regional hub for health and nutrition companies, with Dubai and Abu Dhabi hosting regional headquarters and distribution centers that serve the wider Gulf Cooperation Council (GCC), Middle East, and African markets.• Regulatory oversight for EPA and DHA products in the UAE has been consolidated under a new federal framework. Federal Law No. 38 of 2024 on Medical Products, the Profession of Pharmacy, and Pharmaceutical Establishments came into force on January 2, 2025, replacing Federal Law No. 8 of 2019 and expanding the definition of regulated products to include food supplements. The law designates the Emirates Drug Establishment (EDE) as the central authority for medical product approvals, pharmacovigilance, and market monitoring, and the Ministry of Health and Prevention (MOHAP) has transferred 44 core pharmaceutical services to the EDE in phases, with a further 13 services jointly managed. Food products, including omega-3-fortified foods, are also subject to UAE and GCC standards and emirate-level food safety authorities, such as Dubai Municipality and the Abu Dhabi Agriculture and Food Safety Authority, with halal requirements applying to ingredients such as gelatin capsules.Market Outlook• A defining characteristic of the UAE's EPA & DHA market is the combination of premium consumer demand and rapid regulatory modernization. Affluent residents and a health-conscious expatriate population favor high-concentration triglyceride fish oils, krill oil, algal DHA, and specialized formats such as gummies, liquids, and children's chewables, often purchased through pharmacies and e-commerce.

The consolidation of medical product and supplement regulation under the EDE is expected to streamline product registration, strengthen post-market surveillance, and support faster market entry for compliant international brands, while stricter penalties and pharmacovigilance requirements under Federal Law No. 38 of 2024 are raising quality expectations. Simultaneously, physicians and pharmacists increasingly recommend omega-3 within cardiovascular prevention, prenatal care, and children's nutrition, supported by the expansion of private healthcare networks and preventive health programs.• The market also reflects the UAE's growing emphasis on preventive health and national wellbeing. Federal and emirate-level health authorities promote screening for cardiovascular risk factors, diabetes, and obesity, while national initiatives such as the Emirati Genome Programme are advancing precision and preventive medicine. In infant nutrition, DHA-fortified infant formula is widely available from multinational manufacturers, supported by a young and growing population. The pet nutrition segment is also expanding as pet ownership grows among expatriate and Emirati households, with premium pet foods and supplements incorporating fish oil available through specialty pet stores and online platforms.Market DynamicsDriver: High and early-onset cardiometabolic disease burden supported by premium consumer health spendingThe UAE's EPA & DHA market is primarily driven by the high prevalence of cardiovascular disease, diabetes, obesity, and hypertension, which develop at younger ages than in many other countries. Cardiovascular disease remains the leading cause of death in the UAE, while high rates of overweight and obesity among both nationals and expatriates continue to elevate cardiovascular risk.

Rapid population growth, reaching 11.29 million in 2024, is expanding the consumer base for preventive health products. High disposable incomes and strong awareness of international health trends support spending on premium supplements, with omega-3 among the most commonly recommended products by physicians, pharmacists, and nutritionists. As awareness of cardiovascular prevention continues to grow, pharmacies, hypermarkets, and online platforms are witnessing sustained demand for high-quality EPA and DHA products.Challenge: Import dependence, regulatory transition, and halal and quality compliance requirementsOne of the principal challenges facing the UAE's EPA & DHA market is its near-complete dependence on imported finished products and ingredients, exposing the market to global supply disruptions and raw material price volatility. Peru's first 2026 north-central anchovy quota was set approximately 36% lower than in 2025, following a coastal El Niño event, while the Antarctic krill fishery closed early in both 2025 and 2026. Additionally, the transition to the new federal framework under Federal Law No. 38 of 2024 and the phased transfer of regulatory services from MOHAP to the EDE require companies to adapt registration, labelling, and pharmacovigilance processes. Halal compliance requirements for capsule materials and ingredients, as well as Arabic labelling requirements, add complexity for international brands.

Together, these factors contribute to compliance costs, longer lead times, and premium retail pricing.Trend: E-commerce growth, premium and halal-friendly formats, and regional hub expansionThe UAE is experiencing a significant shift toward digital and premium omega-3 consumption supported by high internet penetration and a strong e-commerce ecosystem. Platforms such as Noon, Amazon.ae, and iHerb, along with pharmacy delivery apps, are expanding access to international omega-3 brands, krill oil, and algal DHA. Halal-certified fish gelatin and plant-based capsules are gaining share, while algal omega-3 is attracting vegetarian consumers, including large South Asian expatriate communities. Simultaneously, the UAE is strengthening its role as a regional hub for health and nutrition companies, with new regulatory pathways under the EDE expected to support faster approvals and regional distribution. The growing emphasis on children's health, prenatal nutrition, and sports nutrition is also boosting demand for DHA- and EPA-rich products.Policies• Federal Law No. 38 of 2024 on Medical Products: In force since January 2, 2025, the law regulates medical products, pharmacists, and pharmaceutical establishments, with an expanded scope that includes food supplements. It introduces stricter post-market surveillance, adverse event reporting, recall requirements, and higher penalties for violations.• Emirates Drug Establishment (EDE): The EDE serves as the central federal authority for medical product approvals, pharmacovigilance, and market monitoring.

MOHAP has transferred 44 core services to the EDE, including manufacturer registration, export certificates, and pharmacovigilance approvals, with 13 services jointly managed, including health advertising approvals.• Food Safety and GCC Standards: Omega-3-fortified foods and certain supplement products are subject to UAE and GCC Standardization Organization (GSO) technical regulations, with registration and inspection by emirate-level authorities such as Dubai Municipality and the Abu Dhabi Agriculture and Food Safety Authority.• Halal Certification and Labelling Requirements: Products and ingredients, including gelatin capsules used for omega-3 softgels, must comply with UAE halal standards, and labels must include Arabic information in line with national and GCC labelling regulations.• Infant Formula Standards: Infant formula marketed in the UAE must comply with GSO and national standards governing composition, including provisions for DHA and ARA, and with regulations restricting the marketing of breast-milk substitutes.Segment AnalysisUAE EPA & DHA Market By Product Type• Docosahexaenoic Acid (DHA) maintains an important position within the UAE, particularly in infant formula, prenatal supplements, and children's chewables and gummies, supported by a young and growing population.• Eicosapentaenoic Acid (EPA) represents the fastest-growing product type segment in the UAE, driven by physician recommendation of high-EPA concentrates and prescription omega-3 medicines for triglyceride management in a population with high rates of diabetes and dyslipidemia.UAE EPA & DHA Market By Source• Fish Oil represents the leading revenue-generating source category in the UAE due to its broad consumer familiarity and the dominance of international fish oil brands in pharmacies and hypermarkets.• Algae Oil maintains a growing position within the UAE, particularly among vegetarian consumers, in prenatal products, and in infant formula, supported by halal-friendly plant-based capsules.• Krill Oil is a premium source category popular among affluent consumers, sold through pharmacies and e-commerce platforms.• Other Marine Sources hold a niche position in the UAE market, including cod liver oil and salmon oil, primarily used in children's supplements and pet nutrition.UAE EPA & DHA Market By Application• Dietary Supplements represent the largest application segment in the UAE, distributed through pharmacies, hypermarkets, health stores, and e-commerce platforms, with international brands dominating.• Pharmaceuticals represent an important application segment, including prescription omega-3 medicines for hypertriglyceridemia and cardiovascular risk management, regulated under Federal Law No. 38 of 2024.• Infant Formula represents a strategically important application segment, with DHA widely included in formulas from multinational manufacturers.• Food & Beverages encompasses omega-3-enriched dairy, eggs, and functional beverages, largely imported and regulated under GCC food standards.• Clinical Nutrition & Medical Foods includes enteral and parenteral nutrition products containing fish oil, used in public and private hospitals.• Pet Nutrition represents the fastest-growing application segment in the UAE, supported by rising pet ownership among expatriate and Emirati households and demand for premium pet foods and supplements.Major EPA & DHA Manufacturers Operating in the UAE• Nature's Bounty, Nordic Naturals, Solgar (Nestlé Health Science), Centrum (Haleon), Jamieson Wellness, Blackmores, Swisse, Abbott, Nestlé, Danone, Aster DM Healthcare, Life Pharmacy, and a range of regional distributors are leading players in the UAE EPA & DHA market, offering finished supplements, DHA-fortified infant formula, and distribution services. Their strong presence, regional distribution networks, halal-compliant product ranges, and relationships with pharmacies and healthcare professionals have driven adoption across the UAE market.• The market is also supported by regional headquarters of multinational companies, logistics providers, free zone operators, and e-commerce platforms that provide import, registration, and distribution support. With its role as a regional trade and healthcare hub, the UAE is a gateway for omega-3 products into the wider GCC and Middle East markets.UAE EPA & DHA Supply and Pricing Economics• EPA and DHA products in the UAE represent premium, largely imported nutritional products whose pricing depends on brand origin, concentration, source, halal certification, and channel. Pricing varies considerably between mass-market fish oil, premium international brands, krill oil, and algal oil.• Retail pricing is influenced by import and logistics costs, registration fees, and global raw material prices. The reduced 2026 Peruvian anchovy quota is expected to place renewed upward pressure on fish oil prices.• Supplements are largely paid out-of-pocket, while prescription omega-3 medicines may be covered by mandatory health insurance schemes in Abu Dhabi and Dubai for eligible patients.• E-commerce and hypermarket promotions intensify price competition, while premium krill and algal products target higher-income consumers.Market Outlook by Consumer Health Spending and Supply Infrastructure• The UAE's EPA & DHA market growth is strongly linked to population growth, high consumer health spending, and the strength of pharmacy and e-commerce channels, although import dependence and the regulatory transition remain significant factors influencing market entry and pricing.• Private consumer spending drives the supplement and pet nutrition segments, while mandatory health insurance supports access to prescription omega-3 for eligible patients.• The future growth opportunity for EPA and DHA in the UAE depends on the effective implementation of Federal Law No. 38 of 2024 and the EDE's consolidated regulatory processes, continued growth of e-commerce, rising demand for halal-friendly and algal omega-3, and the UAE's role as a regional distribution hub. Greater integration of omega-3 within cardiovascular prevention and preventive health programs will likely support long-term market development.Global EPA & DHA MarketConsidered in this report• Historic Year: 2020• Base Year: 2025• Estimated Year: 2026• Forecast Year: 2031Aspects covered in this report• EPA & DHA Market with its value and forecast along with its segments• Various drivers and challenges• Ongoing trends and developments• Top profiled companies• Strategic recommendationsBy Product Type• Eicosapentaenoic Acid (EPA)• Docosahexaenoic Acid (DHA)By Application• Dietary Supplements• Infant Formula• Pharmaceuticals• Food & Beverages• Clinical Nutrition & Medical Foods• Pet NutritionBy Source• Fish Oil• Algae Oil• Krill Oil• Other Marine Sources.